Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0344329 (
collapse
)
28,634
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cell replacement therapy using neural progenitor cells (NPCs) following ischemic stroke is a promising potential therapeutic strategy, but lacks efficacy for human central nervous system (CNS) therapeutics. In a previous
in vitro
study, we reported that the overexpression of human
arginine decarboxylase
(
ADC
) genes by a retroviral plasmid vector promoted the neuronal differentiation of mouse NPCs. In the present study, we focused on the cellular mechanism underlying cell proliferation and differentiation following ischemic injury, and the therapeutic feasibility of NPCs overexpressing
ADC
genes (ADC-NPCs) following ischemic stroke. To mimic cerebral ischemia
in vitro
, we subjected the NPCs to oxygen-glucose deprivation (OGD). The overexpressing
ADC
-NPCs were differentiated by neural lineage, which was related to excessive intracellular calcium-mediated cell cycle arrest and phosphorylation in the ERK1/2, CREB, and STAT1 signaling cascade following ischemic injury. Moreover, the
ADC
-NPCs were able to resist mitochondrial membrane potential
collapse
in the increasingly excessive intracellular calcium environment. Subsequently, transplanted
ADC
-NPCs suppressed infarct volume, and promoted neural differentiation, synapse formation, and motor behavior performance in an
in vivo
tMCAO rat model. The results suggest that
ADC
-NPCs are potentially useful for cell replacement therapy following ischemic stroke.
...
PMID:Restorative Mechanism of Neural Progenitor Cells Overexpressing Arginine Decarboxylase Genes Following Ischemic Injury. 3085 27